Successful gene therapy in utero for lethal murine hypophosphatasia.
暂无分享,去创建一个
J. Millán | M. Migita | T. Shimada | Y. Fukunaga | K. Miyake | A. Watanabe | S. Narisawa | O. Iijima | H. Sugano | Tae Matsumoto
[1] Didier Y. R. Stainier,et al. Molecular control of endothelial cell behaviour during blood vessel morphogenesis , 2011, Nature Reviews Molecular Cell Biology.
[2] J. Millán,et al. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. , 2011, Bone.
[3] N. Miyake,et al. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors , 2011, Brain Research.
[4] J. Millán,et al. Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase. , 2011, Human gene therapy.
[5] P. Zoltick,et al. Early gestational gene transfer of IL-10 by systemic administration of lentiviral vector can prevent arthritis in a murine model , 2011, Gene Therapy.
[6] S. Ikegawa,et al. Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers , 2011, Journal of Human Genetics.
[7] László Négyessy,et al. Layer-specific activity of tissue non-specific alkaline phosphatase in the human neocortex , 2011, Neuroscience.
[8] Jeffrey J. Gray,et al. Enzyme Replacement Therapy Prevents Dental Defects in a Model of Hypophosphatasia , 2011, Journal of dental research.
[9] J. Millán,et al. Prolonged Survival and Phenotypic Correction of Akp2−/− Hypophosphatasia Mice by Lentiviral Gene Therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] M. Whyte. Physiological role of alkaline phosphatase explored in hypophosphatasia , 2010, Annals of the New York Academy of Sciences.
[11] K. Ozono,et al. Clinical Characteristics of Perinatal Lethal Hypophosphatasia: A Report of 6 Cases , 2010, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.
[12] N. Miyake,et al. Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno‐associated viral vector serotype 1 , 2009, The journal of gene medicine.
[13] K. Foust,et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.
[14] R. Terkeltaub,et al. Enzyme Replacement Therapy for Murine Hypophosphatasia , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] Daniel G. Miller,et al. AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma , 2007, Science.
[16] F. Ozturk,et al. Male germ-line cells are at risk following direct-injection retroviral-mediated gene transfer in utero. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] Christof von Kalle,et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] D. Kohn,et al. Fetal gene transfer using lentiviral vectors and the potential for germ cell transduction in rhesus monkeys (Macaca mulatta). , 2005, Human gene therapy.
[19] B. Långström,et al. Pyridoxine effect on synthesis rate of serotonin in the monkey brain measured with positron emission tomography , 2005, Journal of Neural Transmission / General Section JNT.
[20] E. Lehtonen,et al. Evaluation of risks related to the use of adeno-associated virus-based vectors. , 2003, Current gene therapy.
[21] T. Shimada,et al. Bone formation following transplantation of genetically modified primary bone marrow stromal cells , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[22] M. Dallman,et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. , 2003, Blood.
[23] G. Lipshutz,et al. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] J. Millán,et al. Alkaline Phosphatase Knock‐Out Mice Recapitulate the Metabolic and Skeletal Defects of Infantile Hypophosphatasia , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] P. Dijkhuizen,et al. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. , 1999, Human gene therapy.
[26] J. Bergelson,et al. Temporally regulated expression patterns following in utero adenovirus-mediated gene transfer , 1999, Gene Therapy.
[27] A. Salvetti,et al. Factors influencing recombinant adeno-associated virus production. , 1998, Human gene therapy.
[28] J. Millán,et al. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia , 1997, Developmental dynamics : an official publication of the American Association of Anatomists.
[29] J. F. Sharp,et al. Reversal of cystic fibrosis phenotype in mice by gene therapy in utero , 1997, The Lancet.
[30] S. Sasaki,et al. Defection of minor immunological differences among human “universal‐type” alkaline phosphatases , 1988, Journal of cellular biochemistry.